mode of action of the combination product.

The regulatory implications for combination products arise from the obligation to comply with both drug and device regulations, which can impose differing requirements. One pivotal aspect pertains to the UDI system, which was implemented by the FDA to enhance device tracing and adverse event reporting, thereby improving patient safety.

• Primary mode of action: Establish which component of the combination product is the primary mode of action, as this will determine regulatory submission pathways.
• Component classification: Ensure all components are accurately classified as drug or device based on their function and intended use.
• Labeling considerations: Keep in mind that each component may require distinct labeling, particularly with respect to UDI labeling.

Realistically, successful navigation of UDI requirements begins with a comprehensive understanding of the regulatory framework that governs combination products. Begin establishing a compliance framework that integrates UDI considerations into the product lifecycle management from the developmental stage through post-market obligations.

Step 2: Assessing UDI Requirements for Device Components

The UDI system requires that every medical device, including those within combination products, carry specific unique identifiers. This is crucial for ensuring that devices are accurately identified throughout their lifecycle. The FDA has outlined the UDI requirements in the Title 21 of the Code of Federal Regulations (CFR), section 801.20.

For device components of combination products, compliance with UDI requirements entails specific documentation. Following are critical actions to ensure compliance:

• Identify device components: Determine all device components for which a UDI is required, keeping in mind whether the devices are standalone, packaged with a drug, or part of a larger combination product.
• Select an appropriate UDI issuer: UDI numbers may be assigned through the FDA-accredited issuing agency (Interop, GS1, or HIBCC). You must select the appropriate agency to create coherent and compliant identifiers.
• Document preparation: Prepare necessary documentation including device specifications, intended use, and modes of action associated with UDI assignments. Ensure all technical documentation is meticulously organized as outlined in ISO 13485 standards.
• Establish GSPR requirements: For devices matriculating under EU regulations, comply with General Safety and Performance Requirements (GSPR), as detailed in Annex I, before proceeding with UDI requirements.

Proper identification and documentation are paramount. Engage your team early in the process to assess the impact of UDI on product development timelines and potential compliance issues.

Step 3: Preparing for Device Component UDI Submission

Once UDI for device components has been identified, the next action item is to prepare for submission. Each component must have its UDI documented in the Global UDI Database (GUDID), which is critical for tracking and post-market surveillance.

This phase requires a robust routine and accurate documentation practices to ensure that all requirements are met. Key components of the submission process include:

• Understand submission timeline: Assess how UDI submission timelines align with your product development schedule. UDI submissions must be uploaded to the GUDID prior to product launch in the U.S.
• Digital systems readiness: Ensure that your company is equipped with digital systems that can accommodate UDI information management and are integrated with EUDAMED for EU device compliance.
• Documentation of UDI attributes: Collect and prepare detailed documentation of UDI attributes, including device identifier (DI) data and production identifier (PI) information, to accurately describe the device’s life cycle, including its production, distribution, and end user.

It is crucial that your workforce is trained on UDI data requirements and database management to guarantee streamlined submission processes, reducing the likelihood of delays in product launch. Prepare for GUDID entry with checklists and timelines that include milestone laws related to your product.

Step 4: Engaging with Notified Bodies for EU Compliance

For combination products intended for the European market, engaging with Notified Bodies (NBs) is a mandatory step to ensure compliance with the EU Medical Device Regulation (MDR) and In-vitro Diagnostic Regulation (IVDR). The primary role of NBs is to conduct conformity assessments of medical devices and provide certification based on compliance with the respective EU legislation, which now includes the UDI requirements.

Engagement with NBs should be planned in advance of submitting your product to the EU market. Steps to consider include:

• Selection of Notified Body: Choose a Notified Body that is designated for the relevant device classification of your combination products. Review their scope of designation and experience with similar products.
• Pre-Submission Communication: Schedule a pre-submission meeting with the NB to clarify assessment requirements and timelines. Such communications can enhance compliance efficiency.
• Documentation for NB Review: Prepare a comprehensive technical file and ensure it aligns with the requirements specified in the relevant Annex II of the MDR, particularly paying attention to the UDI-related sections.

Engaging with Notified Bodies prior to submission facilitates transparency, making the assessment process smoother and reducing the potential for regulatory setbacks.

Step 5: Executing Post-Market Surveillance and Reporting Obligations

Once a combination product is on the market, adherence to post-market surveillance (PMS) obligations becomes imperative — especially concerning UDI requirements. The PMS framework aims to gather evidence on the clinical performance and safety of the device in the real world. This entails systematically collecting, analyzing, and reporting data derived from UDI information.

The following PMS activities are essential for maintaining compliance and organizational preparedness:

• Real-World Data Collection: Implement systems for systematically collecting real-world data on device performance, user feedback, and adverse events linked to device components.
• UDI Compliance Monitoring: Regularly review and validate the UDI information recorded in GUDID and EUDAMED to ensure consistency and accuracy.
• Reporting to Regulatory Authorities: Prepare for timely submissions of adverse events, recalls, or safety reports to the FDA and relevant European counterparts.

Incorporating PMS into the organization’s ongoing operational strategy will not only foster compliance but also raise the company’s profile as a responsible manufacturer committed to patient safety. An ongoing analysis of PMS data provides insights that may lead to product improvements and post-marketing updates, ensuring the product meets user and regulatory expectations.

Conclusion: Ensuring UDI Compliance for Combination Products

In conclusion, understanding and implementing UDI requirements for device components of combination products is a multi-faceted undertaking. From initiating documentation to engaging Notified Bodies and maintaining compliance through post-market surveillance, each step is essential in achieving regulatory success. The seamless integration of UDI compliance into product strategy not only fulfills regulatory obligations but also reinforces a commitment to patient safety and product quality.

For organizations needing support through these processes, leveraging FDA combination product consulting services could streamline compliance strategies, improve operational efficiencies, and ultimately facilitate successful product launches.